ESTRO 2024 - Abstract Book

S1729

Clinical - Lung

ESTRO 2024

1. Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, et al. Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors. International journal of radiation oncology, biology, physics. 2023. Epub 20230708. doi: 10.1016/j.ijrobp.2023.06.246. PubMed PMID: 37423292. 2. Tekatli H, Giraud N, van Eekelen R, Lagerwaard FJ, Senan S. Ten years outcomes after SABR in central and ultracentral primary lung tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023;188:109848. Epub 20230809. doi: 10.1016/j.radonc.2023.109848. PubMed PMID: 37562553. 3. Regnery S, Ristau J, Weykamp F, Hoegen P, Sprengel SD, Paul KM, et al. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiation oncology (London, England). 2022;17(1):102. Epub 2022/05/26. doi: 10.1186/s13014-022-02070-x. PubMed PMID: 35614486; PubMed Central PMCID: PMCPMC9134672.

2277

Digital Poster

Effect of intervention timing of CRT combined non-third generation EGFR-TKIs in EGFR-mutant NSCLC

guangchuan deng, Zhenxiang Li

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Radiation Oncology, jinan, China

Purpose/Objective:

The probability of brain metastasis (BMs) in lung cancer patients with epidermal growth factor receptor (EGFR) mutation is always high. Craniocerebral radiotherapy is the cornerstone for the treatment of BM, which plays an indispensable role together with EGFR-TKI. However, the timing of intervention in craniocerebral radiotherapy has always been a controversial issue. The purpose of this study was to evaluate the efficacy of intervention timing of craniocerebral radiotherapy combined with first- or second-generation EGFR-TKIs on prognosis of patients with EGFR mutant lung adenocarcinoma complicated with brain metastasis.

Material/Methods:

A total of 603 patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutations were enrolled in this retrospective cohort study. Propensity score matching (PSM) was conducted using a nearest-neighbor algorithm (1:1) to adjust for demographic and clinical covariates. According to whether combined with craniocerebral radiotherapy, the patients were divided into two groups: EGFR-TKIs+craniocerebral radiotherapy group and EGFR TKI alone group. The patients were divided into two groups according to the timing of craniocerebral radiotherapy intervention.: b upfront-group and delay-group. Intracranial progression-free survival (iPFS) and overall survival (OS) were calculated. Kaplan – Meier analysis was used to compare iPFS and OS between the two groups.